Somnairsleep
Baltimore, Maryland
- Seed
- Sleep disorders
Somnair Sleep is developing a non-invasive device option for people with obstructive sleep apnea (OSA). The company aims to improve treatment for OSA patients through medical device innovation informed by the challenges faced by patients and clinicians.
- RaisedTotal raised
- $4.3M
- Jul 2025Latest priced round, Jul 2025
- Seed
- Investors
- 3
- Employees
- 1–10
reccy insights
Somnair’s most consequential reported financing milestone was its $4.3 million Seed round, dated July 7, 2025, with J2 Ventures identified as a lead investor. The financing supports development of the company’s custom-fitted, non-invasive neurostimulation oral appliance for obstructive sleep apnea. The company also received two 2025 program recognitions. On June 24, the UCSF Rosenman Institute named Somnair a 2025 Rosenman Innovator, citing its non-invasive sleep-apnea device. On November 13, Somnair was named to Pepperdine Graziadio’s 2025 Most Fundable Companies list. No specific hiring announcements or key executive changes are identified. Taken together, the dated milestones point to fundraising and startup-program recognition as the clearest public indicators of activity through 2025; they do not establish regulatory clearance or adoption by patients and clinicians.
Written by reccy's AI from company sites, press and funding records · updated Nov 2026
What makes Somnairsleep distinct
- 01Developing a custom-fitted, non-invasive device option for obstructive sleep apnea.
- 02Combines an oral-appliance format with neurostimulation.
- 03The founding team brings experience spanning otolaryngology, medical-device innovation, biomedical engineering, and biodesign.
- 04The company’s mission is informed by observed challenges faced by patients and clinicians.
Technology & products
- Non-invasive Neurostimulation Oral Appliance
A custom-fitted oral device that delivers neurostimulation to treat obstructive sleep apnea without invasive procedures.
- Custom-fitted oral appliance designed to deliver neurostimulation.
- Non-invasive device approach for obstructive sleep apnea treatment.
Recent updates2
- Nov 13, 2025Award
2025 Pepperdine Graziadio Most Fundable Companies
- Jun 24, 2025Award
2025 Rosenman Innovators
Funding
- SeedJul 2025$4.3MLed by J2 Ventures
About Somnairsleep
- Products
- Non-invasive Neurostimulation Oral Appliance
- Leadership
- Anders Sideris, Co-founder and CEO
- Focus areas
- Obstructive Sleep Apnea, sleep health, neurostimulation, medical devices
- Headquarters
- Baltimore, Maryland
- Employees
- 1–10
- Patents granted
- 1